

# Getnet Yimer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3099093/publications.pdf>

Version: 2024-02-01

53  
papers

1,257  
citations

430874

18  
h-index

395702

33  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. PLoS ONE, 2013, 8, e67946.	2.5	108
2	Keratinâ€18 and micro<sc>RNA</sc>â€122 complement alanine aminotransferase as novel safety biomarkers for drugâ€induced liver injury in two human cohorts. Liver International, 2014, 34, 367-378.	3.9	96
3	Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PLoS ONE, 2011, 6, e27810.	2.5	93
4	Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 563-571.	9.1	91
5	Containment of COVID-19 in Ethiopia and implications for tuberculosis care and research. Infectious Diseases of Poverty, 2020, 9, 131.	3.7	76
6	Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 2350-2361.	3.0	54
7	Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients. PLoS ONE, 2014, 9, e94271.	2.5	52
8	Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients. PLoS ONE, 2008, 3, e1809.	2.5	51
9	Â-defensin Genomic Copy Number Is Associated With HIV Load and Immune Reconstitution in Sub-Saharan Africans. Journal of Infectious Diseases, 2012, 206, 1012-1019.	4.0	33
10	Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics, 2016, 17, 755.	2.8	32
11	HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. Frontiers in Pharmacology, 2017, 8, 90.	3.5	32
12	Burden of tuberculosis and challenges related to screening and diagnosis in Ethiopia. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 19, 100158.	1.3	27
13	Elevated levels of circulating CDH5 and FABP1 in association with human drugâ€induced liver injury. Liver International, 2017, 37, 132-140.	3.9	25
14	Antimalarial activity of hydromethanolic extract and its solvent fractions of <i>Vernonia amygdalina</i> leaves in mice infected with <i>Plasmodium berghei</i>. SAGE Open Medicine, 2019, 7, 205031211984976.	1.8	24
15	Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. BMC Pharmacology & Toxicology, 2019, 20, 31.	2.4	23
16	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts <math>\leq 200</math> Cells/µL: TB-HAART Study, a Randomized Clinical Trial. PLoS ONE, 2015, 10, e0122587.	2.5	23
17	<i>SLCO1B1</i> Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. OMICS A Journal of Integrative Biology, 2016, 20, 538-545.	2.0	22
18	Molecular typing of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients in central Ethiopia. BMC Infectious Diseases, 2017, 17, 184.	2.9	21

#	ARTICLE	IF	CITATIONS
19	Campylobacter Colonization, Environmental Enteric Dysfunction, Stunting, and Associated Risk Factors Among Young Children in Rural Ethiopia: A Cross-Sectional Study From the Campylobacter Genomics and Environmental Enteric Dysfunction (CAGED) Project. <i>Frontiers in Public Health</i> , 2020, 8, 615793.	2.7	21
20	CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans. <i>BMC Infectious Diseases</i> , 2013, 13, 536.	2.9	20
21	Ethics in global health research: the need for balance. <i>The Lancet Global Health</i> , 2015, 3, e516-e517.	6.3	19
22	Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmacogene study. <i>Pharmacogenomics</i> , 2015, 16, 1047-1064.	1.3	19
23	Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency. <i>Medicine (United States)</i> , 2016, 95, e4631.	1.0	18
24	Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa. <i>PLoS ONE</i> , 2013, 8, e78165.	2.5	18
25	Annual Tuberculosis Preventive Therapy for Persons With HIV Infection. <i>Annals of Internal Medicine</i> , 2021, 174, 1367-1376.	3.9	17
26	Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia. <i>Nutrients</i> , 2019, 11, 289.	4.1	16
27	Establishment of a Sentinel Laboratory-Based Antimicrobial Resistance Surveillance Network in Ethiopia. <i>Health Security</i> , 2018, 16, S-30-S-36.	1.8	15
28	Traditional medicines for COVID-19: Perspectives from clinical pharmacologists. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3455-3458.	2.4	15
29	Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 207-216.	2.0	12
30	Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. <i>Frontiers in Pharmacology</i> , 2020, 11, 26.	3.5	12
31	Efficacy and Safety of "Fixed Dose" versus "Loose" Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2016, 11, e0157434.	2.5	12
32	Prevalence and Risk Factors of Adverse Drug Reactions Associated Multidrug Resistant Tuberculosis Treatments in Selected Treatment Centers in Addis Ababa Ethiopia. <i>Journal of Tuberculosis Research</i> , 2014, 02, 144-154.	0.2	12
33	Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1538-1549.	2.0	11
34	Impact of early chest radiography on delay in pulmonary tuberculosis case notification in Ethiopia. <i>International Journal of Mycobacteriology</i> , 2021, 10, 364.	0.6	11
35	Effect of <i>Rumex Abyssinicus</i> on preneoplastic lesions in dimethylhydrazine induced colon carcinogenesis in rats. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 365.	3.7	10
36	Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	10

#	ARTICLE	IF	CITATIONS
37	Phenotypic characteristics and asthma severity in an East African cohort of adults and adolescents with asthma: findings from the African severe asthma project. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000484.	3.0	10
38	The Non-Enzymatic Antioxidant and Level of Oxidative Stress of Tuberculosis Patients in Selected Treatment Center in Addis Ababa Ethiopia. <i>Journal of Tuberculosis Research</i> , 2015, 03, 63-71.	0.2	10
39	Tuberculosis Prevalence and Predictors Among Health Care-Seeking People Screened for Cough of Any Duration in Ethiopia: A Multicenter Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021, 9, 805726.	2.7	10
40	Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. <i>British Journal of Pharmacology</i> , 2021, 178, 3294-3308.	5.4	9
41	Skin prick reactivity among asthmatics in East Africa. <i>World Allergy Organization Journal</i> , 2020, 13, 100130.	3.5	9
42	CYP2J2-7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 481.	3.5	8
43	Community engagement and building trust to resolve ethical challenges during humanitarian crises: experience from the CAGED study. <i>Conflict and Health</i> , 2020, 14, 68.	2.7	8
44	Who to Involve and Where to Start Integrating Tuberculosis Screening into Routine Healthcare Services: Positive Cough of Any Duration as the First Step for Screening Tuberculosis in Ethiopia. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 4749-4756.	2.5	8
45	International Clinical Trial Day and clinical trials in Ethiopia and Africa. <i>Trials</i> , 2014, 15, 493.	1.6	7
46	Understanding the key processes of excellence as a prerequisite to establishing academic centres of excellence in Africa. <i>BMC Medical Education</i> , 2021, 21, 36.	2.4	7
47	Short-term impact of celebrating the international clinical trial day: experience from Ethiopia. <i>Trials</i> , 2017, 18, 332.	1.6	6
48	Use of partial N-gene sequences as a tool to monitor progress on rabies control and elimination efforts in Ethiopia. <i>Acta Tropica</i> , 2021, 221, 106022.	2.0	5
49	Conceptualising centres of excellence: a scoping review of global evidence. <i>BMJ Open</i> , 2022, 12, e050419.	1.9	4
50	Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis. <i>International Journal of Mycobacteriology</i> , 2021, 10, 457.	0.6	2
51	Validity of InterVA model versus physician review of verbal autopsy for tracking tuberculosis-related mortality in Ethiopia. <i>BMC Infectious Diseases</i> , 2022, 22, 200.	2.9	2
52	Quality of clinical trials for selected priority mental and neurological disorders in sub-Saharan Africa: a systematic review. <i>Open Access Journal of Clinical Trials</i> , 0, Volume 8, 43-52.	1.5	0
53	PREVALENCE AND RISK FACTORS FOR EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT-ASSOCIATED SEVERE VITAMIN D DEFICIENCY: A PROSPECTIVE COHORT STUDY. <i>BMJ Global Health</i> , 2017, 2, A11.1-A11.	4.7	0